An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small intestine was reported in a patient who received cilta-cel therapy; numerous genetic alterations were identified ...

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel ...

Collaborative studies among veterinarians and oncology researchers are yielding new insights into NHL, inspiring innovative ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Peripheral T cell lymphoma, not otherwise specified (PTCL NOS ... Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in your bloodstream.

"And, importantly, while lymphoma-bearing animals that received ... stages of the disease whose treatment requires a lot of cytotoxic T cell potential. In translating TES further toward human ...

is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess MB-105's safety and efficacy in approximately 46 ...

It changes immune cells called T cells so they target tumors directly. It’s been approved to treat certain types of leukemia and lymphoma. One is diffuse large B-cell lymphoma. CAR T’s not for ...

The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is. Hodgkin lymphoma involves a type of cancer ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates ...